Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER-3: imlunestrant versus endocrine therapy and imlunestrant + abemaciclib in ER-positive, HER2-negative advanced breast cancer
NL-OMON60992Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imlunestrant, abemaciclib, fulvestrant and exemestane in breast cancer, sponsored by Eli Lilly and Company. Primary endpoints: Investigator-assessed progression-free survival between Arm A and Arm B in the ITT population, Investigator-assessed progression-free survival between Arm A and Arm B in the ESR1-mutation detected population and 1 more. Started Aug 2022; status: completed.
02
Drugs
imlunestrantabemaciclibfulvestrantexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60992.